Product Images Docetaxel

This seems to be a table or graph depicting the survival probability of individuals over a certain time period for two different treatments labeled as TAC and 105 FAC. The Survival Probability is shown in the y-axis as percentages from 0 to 80 and the Survival Time is shown in the x-axis as months from 0 to 66. The rest of the text seems to be the labels for the different time intervals on the x-axis.*

This appears to be a chart displaying cumulative probability and overall survival rates over a period of time in months, with a log-rank p value of 0.010. Unfortunately, without more context, it is difficult to provide a more detailed description.*

Not available.*

This appears to be a graph showing survival probability plotted against survival time (in months) at specific intervals (9, 12, 15, and 18 months). However, without more context or labels it is unclear what specific population or condition is being studied.*

This data appears to be a graph displaying probability over time in months. The probability starts at 100% and drops to 12% over the course of 2 months.*

This is a graph or chart that plots "Progression Free Survival Time" (in months) against certain markers or categories labeled on the horizontal axis as "0", "6", "12", "18", "24", "30", "36" and "a2". Without additional context or information it is not possible to determine what these markers or categories represent.*

This chart displays the Survival Probability, represented in percentages, for a given time period of 72 months. The probability starts at 100% and decreases over time, reaching 90% and then 50%. The x-axis represents the Survival Time in months and the corresponding values are given at the bottom of the chart for each interval of six months from 24 to 48.*

This text appears to be a table or a graph showing survival probability percentages for different time durations in months for two groups - TPF (n=255) and PF (n=246). The table provides data for the number of patients at risk for each duration of months.*

PremierProRx® is a brand of Docetaxel Injection, USP useful for IV infusion, distributed by Inc. in Lake Forest, IL, USA. It comes in 2mL single-dose vials with 20 mg/2 L ferintravenous. To be added to the infusion solution checked by the medical professional. It is a cytotoxic drug that should be stored at a temperature range of 20°C to 25°C. The unused portion of the drug should be discarded. The NDC number for this drug is 0409-2956-01. The manufacturer reference number is GUJ-DRUGS/G/28/1267.*

This document appears to be a medication label for Docetaxel Injection, USP, a cytotoxic agent used for intravenous use only. It is ready to add to infusion solutions, and comes in a single-dose vial. Each ml contains 10 mg Docetaxel, polysorbate 80 NF, anhydrous citric acid USP, dehydrated alcohol USP, and Polyethylene Glycol 300 NF. The usual dosage information and handling instructions can be found in the package insert. The medication should be stored between 20°C to 25°C, and should be kept out of reach of children. The document also contains a warning to check concentration prior to preparation.*

This is a medication that comes in a vial containing 80mg/8mL, with each mL containing 10mg of Docetaxel. It also contains Polysorbate 80 NF, Anhydrous Citric Acid USP, Dehydrated Alcohol USP, and Polyethylene. It is ready to be added to an infusion solution and is for intravenous use only. The drug is stable for up to 28 days when stored at the correct temperature and protected from light. It is a prescription medication and the information regarding the dosage, directions for use, and handling can be found in the package insert. The drug should be kept out of reach of children as it is a cytotoxic agent.*

This is a description of a medication called Docetaxel in the form of an injection with a concentration of 160 mg/16 mL, which is intended for intravenous use. This medication should be added to an infusion solution with caution, and the concentration should be checked before preparation. The solution contains several ingredients, including Docetaxel, Polysorbate 80 NF, Anhydrous Citric Acid USP, Dehydrated Alcohol USP, and Polyethylene Glycol 300 NF. The medication should be stored at 20°C to 25°C and protected from light. The packaging insert provides complete instructions on how to use this product. This medication is considered a cytotoxic agent and the usual dosage should be determined by a medical professional. The product is distributed by Hospira, Inc. located in Lake Forest, IL 60045 USA under the PREMIERProRx® brand.*

This is a description of Docetaxel Injection, USP which is ready to add to an infusion solution for intravenous use only. The concentration needs to be checked prior to preparation, and the package insert must be referred to for dosage information and complete instructions. The injection contains 10mg Docetaxel (260mg) and other compounds, such as Polysorbate 80 NF and Polyethylene Glycol 300 NF. It comes in a one-vial formulation and should be kept in its original package between 20°C and 25°C to protect it from light. After the first use, it is stable for up to 28 days when stored between 2°C and 8°C, and protected from light.*